alexa Abstract | Nebracetam Inhibited Hippocampus Neurons Injury Induced by Aβ25-35 in MRTF-A-CArG Manner via ERK1/2 Pathway
ISSN: 2168-9547

Molecular Biology: Open Access
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article Open Access


Nebracetam has been recently proposed to have a neuroprotective action and cognitive enhancing effect being characteristic of a nootropic drug, while the mechanisms remained ambiguity. In this study, we investigated the protective effects of nebracetam on hippocampus neurons injury-induced by β-amyloid protein(Aβ25-35)and its mechanisms. Hippocampus neurons were treated with nebracetam (0.05 mM, 0.2 mM or 0.8 mM) or Aβ25-35 (20 uM/L). We found that Nebracetam significantly reduced apoptotic induced by Aβ25-35 and increase in the total number of dendritic spines and dendritic spine density in a dose-dependent manner. RT-PCR assay and Western blotting analysis revealed that nebracetam increased the expressions of myeloid cell leukemia-1 (Mcl-1), B-cell lymphoma-2 (Bcl-2) and activity regulated cytoskeleton associated protein (Arc) in Aβ25-35-treated hippocampus neurons. Cotreatment nebracetam with MRTF-A (Myocardin-related transcription factor-A) siRNA reversed Mcl-1, Bcl-2 and Arc mRNA and protein levels. What’s more, the luciferase assays indicated that the transcriptional activities of Mcl-1, Bcl-2 and Arc genes were significantly abolished by MRTF-A siRNA while it showed no changes on activities of mut Mcl- 1-promoter-luc, mut Bcl-2-promoter-luc and mut Arc-promoter-luc. Additionally, the up-regulation of Mcl-1, Bcl-2 and Arc protein expressions in nebracetam-treated group was inhibited by extracellular signal regulated protein kinase 1/2 (ERK1/2) inhibitor PH98059. These results demonstrated that nebracetam inhibited Aβ25-35-induced hippocampus neurons injury by enhancing the transactivity of Mcl-1, Bcl-2 and Arc, which may actively based in MRTF-A-CArGdependent manner by thwarting the ERK1/2 pathway.

To read the full article Peer-reviewed Article PDF image | Peer-reviewed Full Article image

Author(s): Tingzi Yin, Xiaolu Cao, Wan Xiao, Ying Zhang, Shuqi Zhao and Xiamin Hu


Nebracetam, Apoptosis, Synaptic plasticity, MRTF-A, ERK1/2 signaling pathway, Nebracetam, Apoptosis, Synaptic plasticity, MRTF-A, ERK1/2 signaling pathway

Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version